CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 69 enrolled
Drug / intervention
eplerenone +3 moredrug
Likely dose
eplerenone 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02525796
NCT02525796Phase 3Completed
CompareCT.gov

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Brigham and Women's Hospital·interventional·Posted Aug 17, 2015·Updated May 3, 2023

In Brief

A Phase 3 clinical trial evaluating eplerenone, amiloride, and 2 other interventions for Primary Hyperparathyroidism. Completed, enrolled 69 participants across 1 site.

Detailed Summary

This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hyperparathyroidism
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 17, 2015
Enrollment StartJan 1, 2016
Primary CompletionOct 1, 2021
Study CompletionOct 2, 2021
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.9 years ago

Interventions

eplerenonedrug

eplerenone, titrated up to a maximum of 50mg BID

amiloridedrug

amiloride, titrated up to a maximum of 10mg BID

Placebodrug

Cinacalcetdrug

Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID